Literature DB >> 3935152

Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats.

S R Kempf, S Ivankovic, M Wiessler, D Schmähl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3935152      PMCID： PMC1977286          DOI： 10.1038/bjc.1985.280

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  12 in total

1.  Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.

Authors:  R J Kociba; S D Sleight
Journal:  Cancer Chemother Rep       Date:  1971-02

2.  Platinum compounds: a new class of potent antitumour agents.

Authors:  B Rosenberg; L VanCamp; J E Trosko; V H Mansour
Journal:  Nature       Date:  1969-04-26       Impact factor: 49.962

3.  Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

Authors:  W Scheef; H O Klein; N Brock; H Burkert; U Günther; H Hoefer-Janker; D Mitrenga; J Schnitker; R Voigtmann
Journal:  Cancer Treat Rep       Date:  1979-03

Review 4.  Cis-diamminedichloroplatinum (II). A new anticancer drug.

Authors:  M Rozencweig; D D von Hoff; M Slavik; F M Muggia
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

5.  Acute and chronic cisplatin nephropathy in rats.

Authors:  D D Choie; D S Longnecker; A A del Campo
Journal:  Lab Invest       Date:  1981-05       Impact factor: 5.662

6.  Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.

Authors:  A B Campbell; S M Kalman; C Jacobs
Journal:  Cancer Treat Rep       Date:  1983-02

7.  High-dose cisplatin in hypertonic saline.

Authors:  R F Ozols; B J Corden; J Jacob; M N Wesley; Y Ostchega; R C Young
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

8.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

Authors:  N Brock; J Pohl; J Stekar; W Scheef
Journal:  Eur J Cancer Clin Oncol       Date:  1982-12

9.  The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  Recent Results Cancer Res       Date:  1980

10.  High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

Authors:  D M Hayes; E Cvitkovic; R B Golbey; E Scheiner; L Helson; I H Krakoff
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860
View more
  5 in total

1.  Carcinogenic effect of cisplatin (cis-diammine-dichloroplatinum (II), CDDP) in BD IX rats.

Authors:  S R Kempf; S Ivankovic
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin.

Authors:  T Wagner; B Kreft; G Bohlmann; G Schwieder
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.

Authors:  M Verschraagen; E Boven; E Torun; C A M Erkelens; F H Hausheer; W J F van der Vijgh
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.